Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

Now watching

Next video starts in : 7 Play

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs
Replay video
Up next

Banks Clear Stress Tests, Gap Sees Sales Decline, Staples Earnings

Unlock your personal NFL Now stream by signing in to NFL.com

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

by TheStreet 0:49 mins

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

by TheStreet 0:49 mins

Bristol-Myers Squibb's murky earnings report reveals a company still in flux. Earnings were slightly above analyst estimates at 48 cents a share. The company's revenue came in at $3.9 billion, down 4% from the same quarter last year. The sales decline is a result of the company selling its stake in a diabetes alliance with AstraZeneca. The company's CEO said, "During the second quarter we delivered strong financial and operating results, invested in key business development opportunities, and achieved important regulatory milestones..." Bristol-Myers is hopeful of winning regulatory approval for its new immunotherapy treatment in the next year as the company looks to narrow its focus on cancer drugs. TheStreet’s Julie Cerullo reports from New York.

TheStreet

Finance

  1. 3:01

    Why nearly 200,000 of these good-paying jobs will go unfilled

  2. 13:33

    Supermarkets soar, the economy's obesity problem and a jobs preview

  3. 2:28

    Don't stress the stress tests

  4. 2:44

    Energy shedding jobs, may impact payroll report

  5. 2:26

    5 tips to protect your money on your smartphone

  6. 12:55

    ECB unveils bond buying details; $21B drug deal; Apple's Achilles' heel?

We The Economy

  1. 6:40

    cave-o-nomics

    14,962 views

  2. 7:38

    Supply & Dance, Man!

    6,132 views

  3. 5:26

    GDP SMACKDOWN

    12,893 views

  4. Lemonade War

    32,963 views

  5. 6:55

    A BEE’S INVOICE; THE HIDDEN VALUE IN NATURE

    2,094 views

  6. 7:06

    Fed Head